Mid-2026 NDA filing could reignite Monopar’s rare-disease rally

Monopar’s next credible stock-moving catalyst is the actual ALXN1840 NDA submission for Wilson disease, which management says remains on track for mid-2026. The setup is attractive because MNPR has a strong cash runway, a tiny float, and very high short interest, but this is now a regulatory-execution story rather than a new-data discovery story. The best near-term trade window is the period just ahead of the expected filing announcement, with upside driven by confirmation that ALXN1840 has formally entered FDA review.

Monopar Therapeutics is now primarily a late-stage rare-disease regulatory story centered on ALXN1840 for Wilson disease. The key value driver is no longer fresh clinical readouts, since the relevant Phase 3 and supportive Phase 2 analyses have already been presented and should be treated as background support. What remains unresolved, and therefore price-setting, is execution of the planned mid-2026 NDA submission to the FDA. If Monopar confirms the filing on schedule, the market is likely to view that as an important derisking step: the company would move from “planning to file” into formal regulatory process, validating management’s timeline and reinforcing the possibility of eventual approval in a rare disease with meaningful unmet need. The company’s balance sheet appears sufficient to carry it through this filing period and beyond, reducing near-term financing overhang. Trading dynamics also matter here: with only about 4.14 million shares in the float and short interest above 38%, even a straightforward filing confirmation could create an outsized move if bears are forced to cover. That said, investors should recognize this is not an undiscovered asset story anymore; much of the clinical enthusiasm is already known, and the catalyst is narrower. The likely upside in the next window is therefore a regulatory-execution rerating rather than a full approval-style repricing. If the NDA is filed on time and communicated clearly, MNPR could retest the upper end of its recent trading range and potentially push into the low-to-mid 80s on momentum and squeeze dynamics.